Bank of Montreal Can Buys 714 Shares of argenx SE (NASDAQ:ARGX)

Bank of Montreal Can lifted its position in shares of argenx SE (NASDAQ:ARGX) by 9.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,307 shares of the company’s stock after acquiring an additional 714 shares during the period. Bank of Montreal Can’s holdings in argenx were worth $4,453,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently modified their holdings of the company. J.Safra Asset Management Corp raised its position in shares of argenx by 590.0% in the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares in the last quarter. Blue Trust Inc. grew its position in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares during the last quarter. Cromwell Holdings LLC boosted its stake in argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new stake in argenx in the second quarter worth $76,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 target price (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. Wells Fargo & Company lifted their price target on shares of argenx from $547.00 to $639.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and increased their target price for the company from $515.00 to $650.00 in a report on Friday, November 1st. JMP Securities upped their price objective on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Citigroup increased their price target on shares of argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and a consensus price target of $635.42.

argenx Trading Down 1.8 %

Shares of ARGX stock opened at $606.47 on Wednesday. argenx SE has a 12-month low of $327.73 and a 12-month high of $622.32. The stock has a 50 day simple moving average of $567.51 and a 200-day simple moving average of $499.76. The company has a market cap of $36.61 billion, a price-to-earnings ratio of -689.17 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period in the prior year, the business earned ($1.25) earnings per share. On average, equities analysts forecast that argenx SE will post 2.2 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.